Related Experiment Videos
[Pregnancy and dilated or hypertrophic cardiomyopathies]
1Clinique cardiologique et des maladies vasculaires, CHU, Nantes.
Insights
Pregnancy outcomes vary for women with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM). While HCM pregnancies are often successful, DCM patients face complications, and peripartum cardiomyopathy carries unpredictable risks.
Area of Science:
- Cardiology
- Reproductive Medicine
- Maternal-Fetal Medicine
Context:
- Pregnancy in women with pre-existing heart conditions like hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM) presents unique challenges.
- Hemodynamic shifts during gestation can exacerbate underlying cardiac pathologies.
- Peripartum cardiomyopathy (PPCM) is a distinct cardiac condition arising late in pregnancy or postpartum.
Purpose:
- To evaluate the risks and outcomes of pregnancy in women with hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM).
- To characterize the specific risks and prognosis associated with peripartum cardiomyopathy (PPCM).
Summary:
- Pregnancy in women with HCM generally has a favorable prognosis with careful management, showing no increased mortality.
- Symptomatic patients with DCM and left ventricular dysfunction experience frequent complications, making pregnancy inadvisable.
- Peripartum cardiomyopathy (PPCM) has an unpredictable course, ranging from full recovery to severe outcomes including cardiac transplantation or death, with high recurrence risk in subsequent pregnancies.
Impact:
- Provides crucial information for managing pregnant patients with cardiomyopathies, guiding clinical decision-making.
- Highlights the differential risks associated with HCM versus DCM during pregnancy.
- Emphasizes the serious nature and unpredictable trajectory of peripartum cardiomyopathy, informing patient counseling and future research.
Abstract:
The risk of pregnancy in women with hypertrophic (HCM) or dilated (DCM) cardiomyopathy may be difficult to assess. Haemodynamic changes occur during pregnancy which may destabilize the underlying cardiac disease. Nevertheless, with or without pharmacological support and with vigilance at the time of childbirth, the outcome of pregnancies in patients with HCM is usually good without extra-mortality. On the other hand, complications often occur in symptomatic patients with DCM and left ventricular dysfunction. Pregnancy is not advisable in this group of patients. Finally, pregnancy may be responsible for a specific type of cardiomyopathy, peripartum cardiomyopathy, a rare condition occurring in the last month or during the 5 following months, which has an unpredictable outcome to complete recovery, myocardial sequellae or aggravation leading to cardiac transplantation or death. These patients are at high risk in future pregnancies.